Evaluation of P53 and BAX gene expression and induction of apoptosis and necrosis by the cis-Pt(II) complex of 3-aminoflavone in comparison with cis-diamminedichloroplatinum(II) (cis-DDP) in human lymphocytes

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 604, Issue 1-2, 2006, Pages 28-35

  Kosmider, Beata ^a   Zawlik, Izabela ^b   Liberski, Pawel P ^b   Osiecka, Regina ^a   Zyner, Elzbieta ^b   Ochocki, Justyn ^b   Bartkowiak, Jacek ^b  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; cis DDP; cis Pt(II) complex of 3 aminoflavone; Human lymphocytes; Necrosis

Indexed keywords

ACRIDINE ORANGE; CISPLATIN; CISPLATIN DERIVATIVE; ETHIDIUM BROMIDE; FLAVONE DERIVATIVE; PROTEIN BAX; PROTEIN P53; TRYPAN BLUE;

APOPTOSIS; ARTICLE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GENOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE; NECROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STAINING;

APOPTOSIS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; CELL CULTURE TECHNIQUES; CELL SURVIVAL; CISPLATIN; DNA PRIMERS; FLAVONOIDS; GENE EXPRESSION REGULATION; GENES, P53; HUMANS; LYMPHOCYTES; NECROSIS; RNA, MESSENGER;

EID: 33645958598     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2005.12.006     Document Type: Article

References (35)

1. Ferguson L.R., and Pearson A.E. The clinical use of mutagenic anticancer drugs. Mutat. Res. 355 (1996) 1-12
2. Danesi R., De Braud F., Fogli S., Di Paolo A., and Del Tacca M. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol. Sci. 22 (2001) 420-426
3. Sikic B.I. Antineoplastic agents. In: Craig C.R., and Stitzel R.E. (Eds). Modern Pharmacology (1982), Little, Brown and Company, Boston 787
4. Reedijk J. Why does Cisplatin Reach Guanine-N7 with Competing S-Donor Ligands available in the cell?. Chem. Rev. 99 (1999) 2499-2510
5. Zyner E., Graczyk J., and Ochocki J. Pt(II) and Pd(II) complexes of 3-aminoflavone: in vitro and in vivo evaluation. Pharmazie 54 (1999) 945-946
6. J. Ochocki, E. Zyner, PL. Patent No. P.185585 (2003).
7. Leite M., Quinta-Costa M., Leite P.S., and Guimarães J.E. Critical evaluation of techniques to detect and measure cell death-study in a model of UV radiation of the leukaemic cell line HL60. Anal. Cell. Pathol. 19 (1999) 139-151
8. Lieberthal W., Triaca V., and Levine J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am. Physiol. Soc. 3 (1996) F700-F708
9. Vermes I., Haanen C., and Reutelingsperger C. Apoptosis and programmed cell death in health and disease. J. Immunol. Meth. 243 (2000) 167-190
10. Anan K., Morisaki T., Katano M., Ikubo A., Tsukahara Y., Kojima M., Uchiyama A., Kuroki S., Torisu M., and Tanaka M. Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: preoperative determination of malignant potential. Eur. J. Surg. Oncol. 24 (1998) 28-33
11. Mori S., Murakami-Mori K., Jewett A., Nakamura S., and Bonavida B. Resistance of AIDS-associated Kaposi's sarcoma cells to Fas-mediated apoptosis. Cancer Res. 56 (1996) 1874-1879
12. Wang T., and Phang T. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 55 (1995) 2487-2489
13. Schottelius A., Brennscheidt U., Ludwig W.-D., Mertelsmann R.H., Herrmann F., and Lübbert M. Mechanisms of p53 alteration in acute leukemias. Leukemia 8 (1994) 1673-1681
14. Bueso-Ramos C.E., Yang Y., DeLeon E., McCown P., Stass S.A., and Albitar M. The human MDM-2 oncogene is overexpressed in leukemias. Blood 82 (1993) 2617-2623
15. Vermes I., and Haanen C. Flow cytometry of apoptotic cell death. Adv. Clin. Chem. 31 (1994) 177-146
16. Prokop A., Wieder T., Sturm I., Essmann F., Seeger K., Wuchter C., Ludwig W.-D., Henze G., Dörken B., and Daniel P.T. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14 (2000) 1606-1613
17. Pietras T., Kakowski R., Zyner E., Stolarek R., Ochocki J., Musiał A., Nowak D., and Glinka R. Deoxiribose degradation by cis-platinum and its derivatives choline, hydroaspartate and aminoflavone. J. Cosmetol. 4 (1998) 177-180
18. Nijveldt R.J., Nood E., Hoorn D.E.C., Boelens P.G., Norren K., and Leeuwen P.A.M. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74 (2001) 418-425
19. Lebeau J., Furman C., Bernier J.-L., Duriez P., Teissier E., and Cotelle N. Antioxidant properties of di-tert-butylhydroxylated flavonoids. Free Rad. Biol. Med. 29 (2000) 900-912
20. Mira L., Fernandez M.T., Santos M., Rocha R., Florêncio M.H., and Jennings K.R. Interactions of flavonoids with iron and copper ions: a mechanism for their antioxidant activity. Free Rad. Res. 36 (2002) 1199-1208
21. Priya S.D., and Devi C.S.S. Protective effect of quercetin in cisplatin-induced cell injury in the rat kidney. Indian J. Pharmacol. 31 (1999) 422-426
22. Weijl N.I., Clenton F.J., and Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat. Rev. 23 (1997) 209-240
23. Kosmider B., Zyner E., Osiecka R., and Ochocki J. Genotoxicity of cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP in A549 cells evaluated by the comet assay. Can. J. Physiol. Pharmacol. 82 (2004) 353-358
24. Kosmider B., Osiecka R., Zyner E., and Ochocki J. Comparison between the genotoxicity of cis-Pt(II) complex of 3-aminoflavone and cis-DDP in lymphocytes evaluated by the comet assay. Drug Chem. Toxicol. 28 (2005) 231-244
25. Erdem A., Kosmider B., Osiecka R., Zyner E., Ochocki J., and Ozsoz M. Electrochemical genosensing of the interaction between the potential chemotherapeutic agent, cis-bis(3-aminoflavone)dichloroplatinum(II) and DNA in comparison with cis-DDP. J. Pharm. Biomed. Anal. 38 (2005) 645-652
26. Kosmider B., and Osiecka R. Flavonoid compounds: a review of anticancer properties and interactions with cis-diamminedichloroplatinum(II). Drug Dev. Res. 63 (2004) 200-211
27. Kartalou M., and Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 478 (2001) 23-43
28. Ciesielska E., Studzian K., Zyner E., Ochocki J., and Szmigiero L. DNA damage and apoptosis induction in L1210 cells by cis-diamminedichloroplatinum(II) and its new aminoflavone analogue. Cell. Mol. Biol. Lett. 5 (2000) 441-450
29. Borner M.M., Joncourt F., and Hotz M.A. Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells. Br. J. Cancer 76 (1997) 1448-1454
30. Choi J.H., Ahn K.S., Kim J., and Hong Y.S. Enhanced induction of Bax gene expression in H460 and H1299 cells with the combined treatment of cisplatin and adenovirus mediated wt-p53 gene transfer. Exp. Mol. Med. 32 (2000) 23-28
31. Boersma A.W.M., Nooter K., Burger H., Kortland C.J., and Stoter G. Bax upregulation is an early event in cisplatin-induced apoptosis in human testicular germ-cell tumor cell line NT2 as quantitated by flow cytometry. Cytometry 27 (1997) 275-282
32. Kosmider B., Wyszynska K., Janik-Spiechowicz E., Osiecka R., Zyner E., Ochocki J., Ciesielska E., and Wasowicz W. Evaluation of the genotoxicity of cis-bis(3-aminoflavone)dichloroplatinum(II) in comparison with cis-DDP. Mutat. Res. 558 (2004) 93-110
33. Kosmider B., Osiecka R., Ciesielska E., Szmigiero L., Zyner E., and Ochocki J. Induction of apoptosis and necrosis in lymphocytes by the cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Mutat. Res. 558 (2004) 169-179
34. Kosmider B., Zyner E., Osiecka R., and Ochocki J. Induction of apoptosis and necrosis in A549 cells by the cis-Pt(II) complex of 3-aminoflavone in comparison with cis-diamminedichloroplatinum(II). Mutat. Res. 563 (2004) 61-70
35. Kosmider B., Wojcik I., Osiecka R., Bartkowiak J., Zyner E., Ochocki J., and Liberski P. Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Invest. New Drugs 23 (2005) 287-297